Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JD Health International, Inc. ( (HK:6618) ) just unveiled an update.
JD Health International Inc. has announced strategic partnerships with major pharmaceutical companies and launched innovative drugs and health products online, reinforcing its position as a leading online marketplace for new and specialty medicines. The company also formed an intelligent interconnected ecosystem alliance with medical device brands to develop a comprehensive smart health management system. Additionally, JD Health has collaborated with Union Hospital to establish an intelligent outpatient service platform, enhancing its ‘Internet + healthcare’ services. Financially, JD Health reported significant growth in revenue and profit for the third quarter of 2025, highlighting its strong performance and market expansion.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$66.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International Inc. operates in the healthcare industry, focusing on providing online healthcare services and products. The company is known for its online marketplace for new and specialty medicine launches and offers a range of pharmaceuticals, nutrition, and health supplements. JD Health is also involved in creating intelligent healthcare ecosystems and AI-driven medical services.
Average Trading Volume: 8,993,890
Technical Sentiment Signal: Buy
Current Market Cap: HK$207.1B
For a thorough assessment of 6618 stock, go to TipRanks’ Stock Analysis page.